 HAIKOU, China, June 9, 2021 PRNewswire -- China Pharma Holdings, Inc. NYSE American: CPHI China Pharma, the Company or We, a specialty pharmaceutical company, today announced plans to launch a highly purified NMNPQQ product following the recent successful completion of a pilot scale test. β-Nicotinamide mononucleotide NMN is a derivative of the B-vitamin niacin, which is believed to significantly improve health and wellness. 